• Mutation; HGNC; HGNC:1455; CALR; Simple; p.Leu367Metfs*43 (c.1099_1159del61); Zygosity=Heterozygous (PubMed=25249012; PubMed=30115971).
  
• Mutation; HGNC; HGNC:7217; MPL; Simple; p.Ser505Asn (c.1514G>A); ClinVar=VCV000014163; Zygosity=Heterozygous (PubMed=30115971).
  
• Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=30115971).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Cys135Tyr (c.404G>A); ClinVar=VCV000141762; Zygosity=Homozygous (PubMed=30115971).
  

PubMed=9406575; DOI=10.1016/S0165-4608(97)00017-4
Yoshida H., Kondo M., Ichihashi T., Hashimoto N., Inazawa J., Ohno R., Naoe T.
A novel myeloid cell line, Marimo, derived from therapy-related acute myeloid leukemia during treatment of essential thrombocythemia: consistent chromosomal abnormalities and temporary C-MYC gene amplification.
Cancer Genet. Cytogenet. 100:21-24(1998)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001)

PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)

PubMed=21552520; DOI=10.1371/journal.pone.0019169; PMCID=PMC3084268
Gu T.-L., Nardone J., Wang Y., Loriaux M., Villen J., Beausoleil S.A., Tucker M., Kornhauser J.M., Ren J.-M., MacNeill J., Gygi S.P., Druker B.J., Heinrich M.C., Rush J., Polakiewicz R.D.
Survey of activated FLT3 signaling in leukemia.
PLoS ONE 6:E19169-E19169(2011)

PubMed=25249012; DOI=10.1038/leu.2014.285; PMCID=PMC4320290
Kollmann K., Nangalia J., Warsch W., Quentmeier H., Bench A., Boyd E., Scott M., Drexler H.G., Green A.R.
MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling.
Leukemia 29:494-497(2015)

PubMed=30115971; DOI=10.1038/s41375-018-0234-6
Han L.-J., Czech J., Maurer A., Brummendorf T.H., Chatain N., Koschmieder S.
Mutant NRAS Q61K is responsible for MAPK pathway activation in the MARIMO cell line and renders these cells independent of the CALR-MPL-JAK2-STAT5 pathway.
Leukemia 32:2087-2090(2018)